BACKGROUND: Activation of the phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway is common in patients with low-grade gliomas (LGGs), but agents that inhibit this pathway, including mTOR inhibitors, have not been studied in this population. METHODS: Fifty-eight patients with pathologic evidence of recurrence after they had initially been diagnosed with World Health Organization (WHO) grade II gliomas were enrolled into a prospective phase 2 clinical trial and received daily everolimus (RAD001) for 1 year or until progression. Tissue at the time of enrollment was analyzed for markers of PI3K/mTOR pathway activation. Thirty-eight patients underwent serial multiparametric magnetic resonance imaging, with the tumor volume and the perfusion metrics (the fractional blood volume [fBV] for capillary density and the transfer coefficient [K ps ] for vascular permeability) measured during treatment. The primary endpoint was progression-free survival at 6 months (PFS-6) in patients with WHO II disease at enrollment. RESULTS: For patients with WHO II gliomas at enrollment, the PFS-6 rate was 84%, and this met the primary endpoint (P <.001 for an improvement from the historical rate of 17%). Evidence of PI3K/mTOR activation by immunohistochemistry for phosphorylated ribosomal S6
INTRODUCTION
The treatment paradigm for low-grade gliomas (LGGs) has evolved rapidly in recent years to include systemic therapy. Radiation Therapy Oncology Group 9802 demonstrated a survival benefit with the addition of procarbazine, lomustine, and vincristine chemotherapy to adjuvant radiotherapy, 1 and several phase 2 studies demonstrated efficacy with either procarbazine, lomustine, and vincristine or temozolomide chemotherapy for patients with newly diagnosed or recurrent
LGGs. [2] [3] [4] [5] [6] However, there is no standard of care for patients with recurrent LGGs, particularly for those who have undergone prior radiation, and this means that there is a compelling need for effective therapy in this population.
Although prior studies have examined the use of cytotoxic chemotherapy, targeted molecular therapy is largely unstudied in LGGs, with limited prior studies showing negative results. 7 Activation of the phosphatidylinositol 3-kinase (PI3K) pathway is commonly seen in LGGs and secondary malignant gliomas, often through inactivation of phosphatase and tensin homolog (PTEN), an inhibitory regulator of the pathway. 8, 9 Immunohistochemistry for downstream targets of PI3K, including phosphorylated ribosomal S6 (p-S6), is seen in more than half of patients with LGGs, and it is associated with PTEN promoter methylation. 10 Furthermore, pathway activation, as measured by these markers, is associated with worse overall survival (OS). Together, these data suggest that PI3K pathway activation is an important driver of glioma progression and thus may be a promising avenue for targeted therapy.
Mammalian target of rapamycin (mTOR) is a downstream target of PI3K that, when activated, leads to abnormal cell growth, proliferation, and angiogenesis. 11, 12 Targeted therapy with the mTOR inhibitor everolimus (RAD001) is highly effective in the treatment of subependymal giant cell astrocytomas in patients with mutations in the tuberous sclerosis complex, a key inhibitor of mTOR, 13 and in the treatment of other solid malignancies with PI3K pathway activation. [14] [15] [16] Here we present the results of a phase 2 clinical trial investigating the efficacy of everolimus in patients with recurrent
LGGs.
MATERIALS AND METHODS

Patient Characteristics
To be eligible, patients had to be older than 18 years; have histologically proven supratentorial, World Health Organization (WHO) grade II oligodendroglioma, astrocytoma, or oligoastrocytoma at the initial diagnosis; and have any number of recurrences before enrollment and any WHO grade at the time of enrollment. Patients were required to have undergone either subtotal resection or biopsy for recurrence or progression within the 4 months before enrollment, and there had to be unequivocal pathologic evidence for tumor recurrence as determined by a neuropathologist at our institution. If the most recent histology demonstrated progression to WHO grade III or IV glioma, patients were required to have undergone prior radiotherapy. Additional inclusion criteria were a Karnofsky performance status 60; adequate hematologic, liver, and renal function on laboratory testing; a fasting cholesterol level 300 mg/dL or 7.75 mmol/L; and a fasting triglyceride level 2.5 times the upper limit of normal. Exclusion criteria included the following: uncontrolled significant medical illness; a history of malignancy in remission for less than 3 years; a known human immunodeficiency virus positive status or AIDS-related illness; gastrointestinal disease altering the absorption of everolimus; impaired lung function with O 2 saturation 88% on room air; prior treatment with an mTOR inhibitor; and being pregnant, breastfeeding, or not using contraception while having childbearing potential. Our institutional review board approved the protocol, and all patients provided informed consent.
Treatment
Everolimus was provided by Novartis (Basel, Switzerland) and was administered orally (10 mg daily) in a fasting state continuously until disease progression, unacceptable toxicity, or 12 months of treatment. Further treatment was allowed at the investigator's discretion. Dose delays and modifications were required for persistent thrombocytopenia (<75 3 19 9 /L), neutropenia (absolute neutrophil count < 1000/mm 3 ), or any persistent nonhematologic grade 2 or 3 toxicity. Discontinuation of everolimus was required for any grade 4 toxicity or any toxicity requiring a treatment interruption of 28 days or longer.
Patient Evaluations
Within the 14 days before the initiation of therapy, all patients underwent a baseline evaluation, which included the following: medical history, neurologic examination, Karnofsky performance status, laboratory testing, pulse oximetry, chest radiograph, and brain magnetic resonance imaging (MRI). Patients were assessed with a neurologic examination, laboratory testing, and MRI every 2 months during the first 12 months of treatment and every 3 months thereafter.
Treatment Response Evaluation
The assessment of the treatment response was based on the Response Assessment in Neuro-Oncology criteria, 17, 18 as determined by MRI in conjunction with steroid requirement. A complete response was defined as the disappearance of all measurable disease while the patient was on minimal or no steroids; a partial response was defined as a 50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions, with no new lesions on stable or decreasing doses of steroids; and progressive disease was defined as a 25% increase in the sum of the products of all measurable lesions, clear worsening of any evaluable disease, or any new lesions. All other situations were considered stable disease.
Molecular Analysis
All patients with available tissue were evaluated for activation of the PI3K/mTOR pathway. Immunohistochemistry was performed for phosphorylated proline-rich 
Multiparametric Imaging
A subset of 38 patients underwent research imaging at our institution with multiparametric MRI at the time of study enrollment and then every 2 months during treatment; this included T2 fluid-attenuated inversion-recovery (FLAIR) imaging, T1 with/without gadolinium contrast, dynamic contrast-enhanced perfusion-weighted imaging (DCE-PWI), and diffusion-weighted imaging (DWI). The lesion volume was defined as the hyperintense region on FLAIR along with any contrast-enhancing region, and it was manually defined. Quantitative metrics, including the transfer coefficient (K ps ) and fractional blood volume (fBV) from DCE-PWI and the apparent diffusion coefficient (ADC) from DWI, were then assessed within the tumor region at each time point.
Statistical Design
The primary endpoint was progression-free survival at 6 months (PFS-6), which was measured for patients with WHO grade II gliomas at enrollment. The secondary endpoints included the radiographic response rate, OS from the time of study enrollment, and toxicity. Because of a dearth of clinical data for recurrent LGGs at the time of the study's design, a null hypothesis was extrapolated from studies of malignant gliomas showing a PFS-6 rate of 17% 20 ; using a 1-tailed binomial exact test with an a value of .05, the study was powered to detect a difference in PFS-6 from 17% if the true PFS-6 rate was 40% with 90% power. On the basis of this sample size calculation, the enrollment of 40 patients with low-grade histology at enrollment was planned, with the accrual of additional patients with high-grade histology allowing for correlative studies but not included in the primary and secondary endpoint analyses. The influence of clinical, molecular, and radiographic parameters on survival was assessed with a Cox proportional hazards analysis, and changes in imaging parameters were assessed with the Wilcoxon rank-sum test. Adjustments for the testing of multiple imaging and molecular parameters were not performed because the results were considered to be hypothesisgenerating. A classification and regression tree (CART) analysis was performed to generate binary thresholds for continuous molecular markers. To minimize cohort heterogeneity, the relations between survival endpoints and clinical and molecular factors were assessed only for patients with WHO II gliomas at enrollment.
RESULTS
Patient Characteristics
Fifty-eight patients were enrolled in the trial from 2009 to 2015, with the patient characteristics summarized in Table 1 . Forty-seven patients (81%) had WHO grade II disease at study enrollment, whereas 11 (19%) had WHO grade III/IV disease. Only 1 patient with WHO II disease was in the isocitrate dehydrogenase wild type (IDHwt) molecular subgroup, so the 1p/19q intact/isocitrate dehydrogenase mutated (IDHmut) and IDHwt groups were combined into a single group (1p/19q intact) for subsequent analysis.
Survival Endpoints
The median follow-up for all patients was 3.5 years; there were 45 progression events and 16 deaths during followup. All patients were evaluable for the primary endpoint of PFS-6. For patients with WHO grade II disease at enrollment, we observed a PFS-6 rate of 84% (95% confidence interval [CI], 71%-94%), and this met the primary endpoint (P < .001 for improvement from a historical rate of 17%). The PFS-6 rate for patients with WHO grade III/IV disease at enrollment was 55% (95% CI, 24%-83%). The median progression-free survival (PFS) was 1.4 years (95% CI, 1.2-1.9 year) and 0.6 years (95% CI, 0.1 years to not available), whereas the median OS was not reached (lower 95% CI, 4.0 years) and 2.9 years (95% lower CI, 1.6 years) for WHO II and III/IV, respectively (Fig. 1A,B) . Table 2 shows survival outcomes for patients with WHO II disease at enrollment according to clinical, molecular, and radiographic factors.
Treatment Response and Disease Progression
There were no complete or partial radiographic responses. Seventeen patients (29%) progressed during the first year of therapy; they included 10 with WHO II disease (21%) and 7 with WHO grade III/IV disease (64%) at enrollment. Twenty-seven patients (47%) completed at least 1 year of treatment without progression, and 23 of these patients (49%) had WHO II disease at enrollment. Twelve patients discontinued treatment during the first year without progression, and 2 patients remained on treatment with less than 1 year of follow-up.
Treatment Compliance and Toxicity
The median treatment duration was 11 months (range, 1-28 months); 8 patients (14%) discontinued treatment because of toxicity. There were no grade 4 or 5 toxicities; lesser grade toxicities are shown in Table 3 .
PI3K/mTOR Pathway Activation
Activation of the PI3K pathway at the time of recurrence was assessed for 50 patients (86%), including 41 of 47 (87%) with WHO II disease at enrollment, via immunohistochemistry for multiple markers (Table 1) . In general, patients with a 1p/19q codeletion had lower median staining for PI3K activation than 1p/19q intact patients (Supporting Table 1 [see online supporting information]).
Although staining for p-mTOR, p-PRAS40, and p-4EBP1 showed no relation with survival outcomes (Supporting Table 2 Ser240/244 staining was also associated with shorter OS as measured from the time of the initial diagnosis (HR for each 10% increase, 1.37; 95% CI, 1.12-1.67). Using a binary threshold determined by CART analysis with OS as the endpoint, we found that p-S6 Ser240/244 positivity (19%) was prognostic of shorter PFS (HR, 3.03; 95% CI, 1.42-6.47) and OS (HR 12.7; 95% CI, 1.57-102) from the time of study enrollment (Fig. 1E,F) . Staining for a second p-S6 epitope (p-S6 Ser235/236 ) was performed independently and yielded similar results (Table 2) . Positivity for p-S6 was the only clinical or molecular factor found to be prognostic of PFS.
Multiparametric MRI
In an exploratory analysis, multiparametric MRI was performed at the baseline and every 2 months on therapy for 38 patients (32 with WHO II and 6 with WHO grade III/IV), and quantitative metrics of the tumor size (the volume of FLAIR hyperintensity), cellular density (ADC from DWI), and vascular characteristics, including the capillary density and vascular permeability (fBV and K ps , respectively, from DCE-PWI), were assessed (Fig. 2) . Baseline radiographic characteristics were not significantly associated with PFS (Supporting Table 2 [see online supporting information]). However, there was a significant decrease in the median fBV after 6 months of therapy (median decrease, 15%; interquartile range, 4%-39%; P 5 .026) and a trend toward a significant decrease in the median K ps value (median decrease, 12%; interquartile Original Article range, 2%-23%; P 5 .087). Decreases in both fBV and K ps after 6 months were associated with improved PFS (HR for each 10% decrease in fBV, 0.71; 95% CI, 0.53-0.92; HR for each 10% decrease in K ps , 0.82, 95% CI, 0.67-0.99). There were no significant changes in the tumor volume or ADC during therapy (Table 4) .
DISCUSSION
Although adjuvant radiotherapy and chemotherapy are now considered the standard of care for most patients with newly diagnosed LGGs, 1 there is no standard treatment for patients at disease recurrence, particularly for patients who have already received radiotherapy. Thus, there is a significant need for effective systemic therapy for patients with recurrent LGGs, and there is increasing interest in the incorporation of systemic agents into adjuvant therapy. Activation of the PI3K/mTOR pathway is common in adults with LGGs, 10 but the efficacy of agents inhibiting this pathway has not been prospectively studied.
We report results from a phase 2 study investigating the use of everolimus (RAD001), an mTOR inhibitor, in patients with recurrent LGGs. Even though our study population consisted of pretreated patients, our study met the primary endpoint with a PFS-6 of 84% for patients with WHO II disease at enrollment. We also observed a high rate of disease stability, with 48% of the patients completing 1 year of therapy without progression. Treatment compliance was high with a manageable toxicity profile.
Although the prespecified primary endpoint was met, conclusions regarding clinical efficacy are limited by the combination of our single-arm study design and the lack of an appropriate historical control population at the time when the study was designed; this required extrapolation from data for patients with malignant gliomas. 20 As a result, the population used to generate our null hypothesis likely constituted a molecularly distinct group, predominantly IDHwt, in contrast to our study population of predominantly IDHmut patients.
However, our median PFS of 17 months compares favorably with the median of 10 months from a study of recurrent LGGs reported after our study was designed. 7 Only 38% and 19% of the patients in that study had received prior chemotherapy and radiotherapy, respectively, whereas 72% and 28%, respectively, had received them in our study. Although the authors did not report PFS-6 and this precluded a direct comparison with our primary endpoint, a power analysis for the median PFS indicated that our study had 89% power to detect a significant difference in the median PFS with an a value of .05. Thus, had our study been designed with these more recent data as a null hypothesis, it would have been powered to detect a significant improvement in the median PFS. However, because this was a post hoc analysis using an endpoint other than our primary endpoint, these results should be interpreted with caution. Thus, compared with the limited prior literature on recurrent LGGs, our study shows encouraging results for a more heavily pretreated cohort. Because of the dearth of data for this population, our results may serve as a historical comparator for future investigations.
To our knowledge, this is the first study evaluating mTOR inhibition in LGGs. Prior studies evaluating mTOR inhibition in glioblastomas have yielded mixed results, with modest rates of response and scant evidence of improvements in clinical outcomes. [21] [22] [23] [24] However, in contrast to LGGs, glioblastomas are characterized by a higher mutational burden, with alterations of multiple redundant cell signaling pathways, 25 and this suggests that mTOR inhibition as monotherapy may provide limited clinical efficacy. Agents inhibiting mTOR may provide a benefit in higher grade tumors only in combination with other agents; this approach has been successful for other solid tumors.
14 A unique strength of our study was that tissue confirming disease recurrence was obtained for all patients within the 4 months before their enrollment, and this allowed a comprehensive prospective assessment of the molecular diagnosis 19 and of the PI3K/mTOR pathway activation status at the time of treatment, which is of critical importance because of the known evolution of tumor genomic properties during the course of therapy. 26 Several markers of the PI3K/mTOR pathway were examined, but only p-S6 was found to be of significant prognostic value, with p-S6 Ser240/244 epitope positivity associated with worse PFS and OS from the time of study enrollment and with worse OS from the time of the initial diagnosis; this indicates that activation of the PI3K/mTOR pathway may negatively affect the overall disease prognosis. These Abbreviations: ADC, apparent diffusion coefficient; CI, confidence interval; fBV, fractional blood volume; IQR, interquartile range; K ps , transfer coefficient; PFS, progression-free survival. The median parameter values within the T2 FLAIR tumor volume were calculated for the diffusion and perfusion parameters. For each parameter, the percentage change after 6 months of therapy is reported along with the P value for a significant change from the baseline (Wilcoxon rank-sum test). A Cox proportional hazards model was used to evaluate the relation between radiographic changes and progression-free survival, with hazard ratios reported for each 10% decrease in the parameter.
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results were also validated through independent staining for a separate epitope (S6 Ser235/236 ). Our results are consistent with prior retrospective studies demonstrating the prognostic value of p-S6 10 and thus further support the utility of p-S6 as a clinically meaningful marker of PI3K/ mTOR pathway activation.
The fact that p-S6 remains a negative prognostic factor despite the use of mTOR inhibition does not suggest a lack of drug efficacy because our study lacked a control arm of p-S6-positive patients not receiving mTOR to serve as a comparator. Further work is needed to determine whether p-S6 serves as a predictive marker for the efficacy of PI3K/mTOR pathway inhibition. Furthermore, there were too few patients in the IDHwt molecular subgroup to assess whether p-S6 remains prognostic after accounting for the molecular status according to the 2016 WHO classification 19 ; further work is also needed to validate p-S6 as an independent prognostic marker in addition to standard molecular markers.
In an exploratory analysis, we prospectively performed multiparametric MRI for 38 patients in the study and assessed tumor perfusion and diffusion properties at the baseline and during treatment to allow an assessment of in vivo modulation of tumor physiologic properties with therapy. We found a substantial decrease in tumor vascular permeability and capillary density after 6 months of treatment, as measured by perfusion MRI. These alterations are consistent with the known antiangiogenic properties of mTOR inhibitors via modulation of downstream HIF-1a signaling. 27, 28 We also found that larger decreases in both capillary density and vascular permeability during therapy were associated with improved PFS, and this suggests that these changes correspond to clinically meaningful outcomes. Because of the lack of the volumetric response commonly seen in LGGs, an assessment of validated radiographic markers probing tumor microstructure and vascular properties may be an important component of future studies.
Several limitations to our study should be mentioned. First, although molecular and radiographic analyses were performed prospectively, data were not available for analyses for all patients in the study. Second, the binary threshold for p-S6 positivity derived from the CART analysis has not been validated with an independent data set. In addition, because patients underwent resection before study enrollment, our finding of decreased tumor perfusion during treatment is potentially confounded by postoperative changes unrelated to the effect of treatment. However, decreased perfusion was shown to be associated with improved PFS, and this would not be expected from standard postoperative changes. These molecular and radiographic results should be considered exploratory in nature and thus require further validation. Finally, there were few OS events in our cohort, so results relating to this endpoint should be interpreted with caution.
In conclusion, in a pretreated population of patients with recurrent LGGs, we have demonstrated a high rate of disease stability during therapy with everolimus, but conclusions from the study regarding clinical efficacy are limited by the lack of a control arm. However, we have provided radiographic evidence of alterations in the tumor vasculature during therapy, and this is consistent with the antiangiogenic properties of mTOR inhibitors. A prospective molecular analysis supports the use of p-S6 as a clinically meaningful prognostic marker in recurrent
LGGs. Our results support further investigation of the utility of everolimus in this population; a study for patients with newly diagnosed LGGs is underway at our institution.
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